Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1964440

AVI BioPharma Inc. - Product Pipeline Review - H2 2011

Description:

AVI BioPharma Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “AVI BioPharma Inc. - Product Pipeline Review - H2 2011” provides data on the AVI BioPharma Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, AVI BioPharma Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from AVI BioPharma Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- AVI BioPharma Inc. - Brief AVI BioPharma Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AVI BioPharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of AVI BioPharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AVI BioPharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate AVI BioPharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AVI BioPharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AVI BioPharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AVI BioPharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AVI BioPharma Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of AVI BioPharma Inc.; AVI BioPharma Inc. - Key Therapeutics; AVI BioPharma Inc. - Pipeline Overview and Promising Molecules; AVI BioPharma Inc. - News; AVI BioPharma Inc. - Latest Updates; AVI BioPharma Inc. - Pipeline; AVI BioPharma Inc. - Discontinued/Dormant Projects

Contents:

List of Tables
List of Figures
AVI BioPharma Inc. Snapshot
AVI BioPharma Inc. Overview
Key Information
Key Facts
AVI BioPharma Inc. – Research and Development Overview
Key Therapeutic Areas
AVI BioPharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
AVI BioPharma Inc. – Pipeline Products Glance
AVI BioPharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
AVI BioPharma Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
AVI BioPharma Inc. – Drug Profiles
AVI-3378
Product Description
Mechanism of Action
R&D Progress
AVI-4065
Product Description
Mechanism of Action
R&D Progress
AVI-4658
Product Description
Mechanism of Action
R&D Progress
AVI-5038
Product Description
Mechanism of Action
R&D Progress
AVI-6002
Product Description
Mechanism of Action
R&D Progress
AVI-6003
Product Description
Mechanism of Action
R&D Progress
AVI-6006
Product Description
Mechanism of Action
R&D Progress
AVI-7012
Product Description
Mechanism of Action
R&D Progress
AVI-7100
Product Description
Mechanism of Action
R&D Progress
Resten-NG
Product Description
Mechanism of Action
R&D Progress
AVI BioPharma Inc. – Pipeline Analysis
AVI BioPharma Inc. – Pipeline Products by Therapeutic Class
AVI BioPharma Inc. - Pipeline Products By Target
AVI BioPharma Inc. – Pipeline Products by Route of Administration
AVI BioPharma Inc. – Pipeline Products by Molecule Type
AVI BioPharma Inc. – Recent Pipeline Updates
AVI BioPharma Inc. - Dormant Projects
AVI BioPharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AVI-4020
AVI-4065
AVI BioPharma Inc. – Company Statement
AVI BioPharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Mar 30, 2005: AVI BioPharma Announces Publication Of West Nile And Dengue Virus NEUGENE Antisense Studies In The Journal Of Virology
Oct 29, 2003: AVI BioPharma Updates Progress On Infectious Disease Program Using NeuGene Antisense For RNA Viruses
Aug 25, 2009: AVI BioPharma Announces To Present Full Data Of Phase I Trial For AVI-4658
Jul 25, 2011: The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant And Dose-Dependent Expression Of Dystrophin In Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen
Mar 25, 2010: AVI BioPharma To Present Update On AVI-5038 For Treatment Of Duchenne Muscular Dystrophy
Aug 24, 2010: AVI BioPharma Announces Positive Results Against Human Pandemic H1N1 Influenza Virus In Preclinical Studies of AVI-7100
Dec 23, 2008: AVI BioPharma Announces FDA Clearance Of IND Applications For Clinical Trials Of RNA Therapeutic Agents AVI–6002 and AVI–6003
Dec 23, 2008: AVI BioPharma Announces FDA Clearance Of IND Applications For Clinical Trials Of RNA Therapeutic Agents For Treatment Of Ebola And Marburg Viruses.
Oct 21, 2011: AVI BioPharma's RNA-Based Therapeutic For Treatment Of Ebola Virus Shows Positive Safety Data In Phase I Clinical Study
Oct 21, 2011: AVI BioPharma's RNA-Based Therapeutic For Treatment Of Marburg Virus Shows Positive Safety Data In Phase I Clinical Study
Jun 21, 2011: AVI BioPharma Expands Clinical Pipeline With Initiation Of Phase I Study Of Influenza Therapeutic Candidate
Apr 20, 2006: AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
Oct 19, 2006: AVI BioPharma Presents Successful Trial Results Using NeuGene Antisense To Alter Drug Metabolism In Humans
Sep 19, 2011: AVI BioPharma Announces Presentations At 51st Interscience Conference On Antimicrobial Agents And Chemotherapy Annual Meeting
Jul 19, 2003: AVI Begins Phase II Study Of Resten-NG In Restenosis.
Oct 18, 2011: AVI BioPharma Announces Data Presentation For Eteplirsen At 16th International World Muscle Society Congress
Sep 18, 2003: AVI BioPharma Reports Positive Phase II Clinical Results In Restenosis.
Mar 18, 2004: AVI Reports Positive Clinical Results On Oral Delivery Of Its NeuGene Antisense Drug
Jul 17, 2010: AVI BioPharma Announces Presentations On AVI-4658 For Treatment Of Duchenne Muscular Dystrophy At International Congress On Neuromuscular Diseases
Nov 16, 1999: AVI BioPharma Files IND Application For Resten-NG.
Oct 15, 2010: AVI BioPharma Announces Encouraging Results From Phase Ib/II Study Of AVI-4658 In Treatment Of Duchenne Muscular Dystrophy
Aug 15, 2011: AVI BioPharma Initiates Dosing In Phase II Study Of Eteplirsen In Duchenne Muscular Dystrophy Patients
Oct 14, 2008: AVI BioPharma Receives Provisional GTAC Approval For Drug AVI–4658 In United Kingdom.
Sep 14, 2009: AVI BioPharma Completes Phase I Trial Of AVI-4658
Sep 14, 2009: AVI BioPharma Demonstrates Effectiveness Of Immune Control In Hemorrhagic Virus Infections.
Aug 14, 2003: AVI Files For Orphan Designation For Its SARS Coronavirus Antisense Drug AVI-4179
Apr 12, 2011: AVI BioPharma To Present Data For RNA-Based Duchenne Muscular Dystrophy Drug Candidate At 63rd Annual Meeting Of American Academy of Neurology
Oct 11, 2010: AVI BioPharma To Present Data Of AVI-4658 At 15th International Congress Of World Muscle Society
Apr 11, 2011: AVI BioPharma Receives Approval Of Nonproprietary Name Eteplirsen For Duchenne Muscular Dystrophy Therapeutic Candidate, AVI-4658
Nov 10, 2004: AVI BioPharma Announces Results Of Phase II Clinical Trial Resten-NG .
Jun 09, 2011: AVI BioPharma Provides Update On Initiation Of Eteplirsen Phase II Clinical Trial
Dec 07, 2006: AVI BioPharma Announces Clinical Development Initiative For Muscular Dystrophy
Jul 07, 2010: Alnylam Doses ATTR Patients In Phase I Clinical Study Of ALN-TTR01
Jul 07, 2010: AVI Opens IND Application For AVI-4658 In Duchenne Muscular Dystrophy
Jul 07, 2003: AVI BioPharma Manufactures West Nile Virus Antisense Drug New GMP Manufacturing Facility Produces Drug For Clinical Trials
Feb 05, 2010: AVI BioPharma’s AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy
May 04, 2011: AVI BioPharma Initiates Phase I Clinical Study Of AVI-6002 For Treatment Of Ebola Viruses
May 04, 2011: AVI BioPharma Initiates Phase I Clinical Study Of AVI-6003 For Treatment of Marburg virus
Feb 04, 2010: AVI BioPharma GLP Safety Pharmacology And Genotoxicity Evaluations Of AVI-4658 For Duchenne Muscular Dystrophy Published In The International Journal Of Toxicology
Dec 03, 2008: AVI BioPharma Files IND For Clinical Trial For The Treatment Of Ebola Virus .
Dec 03, 2008: AVI BioPharma Files IND For Clinical Trial For The Treatment Of Ebola Virus and The Preclinical Results Of AVI-6003 .
Dec 03, 2007: AVI BioPharma Receives Fast Track Designation For AVI–4658.
Financial Deals Landscape
AVI BioPharma Inc., Deals Summary
AVI BioPharma Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
AVI BioPharma Enters Into Co-Development Agreement With Karolinska Institute
AVI BioPharma Enters Into Co-Development Agreement With DTRA
AVI BioPharma Enters Into Agreement With Action Duchenne
Avi Biopharma Signs An Agreement With Cook Medical
AVI BioPharma Enters Into Co-Development Agreement With WRAIR
Licensing Agreements
AVI BioPharma Enters Into Agreement With Ercole Biotech
AVI BioPharma Enters Into Licensing Agreement With Eleos
Eleos Enters Into Licensing Agreement With AVI BioPharma
AVI BioPharma Enters Into Licensing Agreement With Ercole Biotech
AVI BioPharma Enters Into Licensing Agreement With Chiron
Equity Offering
AVI BioPharma Completes An Underwritten Public Offering Of Its Common Stock For $34.5 Million
AVI BioPharma Completes Public Offering Of $34.5 Million
AVI BioPharma Completes Private Placement Of $16.5 Million
AVI BioPharma Completes Private Placement Of $20.3 Million
AVI BioPharma Completes Private Placement Of $23 Million
AVI BioPharma Completes Private Placement Of $24 Million
AVI BioPharma Raises $7.5 Million From Exercise Of Warrants
Acquisition
AVI BioPharma Acquires Ercole Biotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
AVI BioPharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
AVI BioPharma Inc. – Pipeline by Stage of Development, H2 2011
AVI BioPharma Inc. - Phase II, H2 2011
AVI BioPharma Inc. - Phase I, H2 2011
AVI BioPharma Inc. - Pipeline By Therapeutic Class, H2 2011
AVI BioPharma Inc. - Pipeline By Target, H2 2011
AVI BioPharma Inc. – Pipeline By Route of Administration, H2 2011
AVI BioPharma Inc. – Pipeline By Molecule Type, H2 2011
AVI BioPharma Inc. – Recent Pipeline Updates, H2 2011
AVI BioPharma Inc. - Dormant Developmental Projects, 2010
AVI BioPharma Inc. - Discontinued Pipeline Products, 2010
AVI BioPharma Inc., Other Locations
AVI BioPharma Inc., Deals Summary
AVI BioPharma Enters Into Co-Development Agreement With Karolinska Institute
AVI BioPharma Enters Into Co-Development Agreement With DTRA
AVI BioPharma Enters Into Agreement With Action Duchenne
Avi Biopharma Signs An Agreement With Cook Medical
AVI BioPharma Enters Into Co-Development Agreement With WRAIR
AVI BioPharma Enters Into Agreement With Ercole Biotech
AVI BioPharma Enters Into Licensing Agreement With Eleos
Eleos Enters Into Licensing Agreement With AVI BioPharma
AVI BioPharma Enters Into Licensing Agreement With Ercole Biotech
AVI BioPharma Enters Into Licensing Agreement With Chiron
AVI BioPharma Completes An Underwritten Public Offering Of Its Common Stock For $34.5 Million
AVI BioPharma Completes Public Offering Of $34.5 Million
AVI BioPharma Completes Private Placement Of $16.5 Million
AVI BioPharma Completes Private Placement Of $20.3 Million
AVI BioPharma Completes Private Placement Of $23 Million
AVI BioPharma Completes Private Placement Of $24 Million
AVI BioPharma Raises $7.5 Million From Exercise Of Warrants
AVI BioPharma Acquires Ercole Biotech

List of Figures
AVI BioPharma Inc. – Pipeline by Therapy Area and Indication, H2 2011
AVI BioPharma Inc. – Pipeline by Stage of Development, H2 2011
AVI BioPharma Inc. – Pipeline By Therapeutic Class, H2 2011
AVI BioPharma Inc. - Pipeline By Target, H2 2011
AVI BioPharma Inc. – Pipeline By Route of Administration, H2 2011
AVI BioPharma Inc. – Pipeline By Molecule Type, H2 2011

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Wednesday, May 22, 2013
6:51:32 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

AVI BioPharma Inc. - Product Pipeline Review - H2 2011

Web Address

http://www.researchandmarkets.com/reports/1964440

Office Code

OC8DIQSPPMPTQT

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Wednesday, May 22, 2013
6:51:32 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

AVI BioPharma Inc. - Product Pipeline Review - H2 2011

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)